Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Tengji (Xiamen) Biomedical Technology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Fatty Liver, Alcoholic|Hepatitis B, Chronic|Hepatitis, Alcoholic|Metabolic Dysfunction-Associated Steatohepatitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07589400 |
ACT500-4/003 | P1 |
Not yet recruiting |
Hepatitis B, Chronic |
2027-03-30 |
12% |
2026-05-16 |
Primary Endpoints |
NCT07462455 |
MASLD | P1 |
Not yet recruiting |
Metabolic Dysfunction-Associated Steatohepatitis |
2027-02-28 |
12% |
2026-03-11 |
|
NCT06716905 |
ACT500-4/01 | P1 |
Completed |
Metabolic Dysfunction-Associated Steatohepatitis|Hepatitis, Alcoholic|Fatty Liver, Alcoholic |
2025-09-22 |
2026-02-18 |
||
CTR20254066 |
CTR20254066 | P1 |
Completed |
Hepatitis, Alcoholic|Metabolic Dysfunction-Associated Steatohepatitis |
2025-11-20 |
2026-02-15 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244213 |
CTR20244213 | P1 |
Completed |
Hepatitis, Alcoholic|Metabolic Dysfunction-Associated Steatohepatitis |
2025-09-22 |
2026-02-15 |
Patient Enrollment|Primary Completion Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/12/2025 |
News Article |
Delta's UFC 500 Ultra-Fast EV Charger Achieves German Eichrecht Certification |